Cyclophilin Inhibitors
Cyclophilin Inhibitors
复制标题
DOI：
10.1016/j.cld.2009.05.002
复制
发表时间：
2009-08-01
影响因子：
5.1
通讯作者：
Gallay, Philippe A.
中科院分区：
文献类型：
--
作者：
Gallay, Philippe A.
自引入聚乙二醇化干扰素-α（pIFNa）和利巴韦林（RBV）治疗以来，达到持续抗病毒应答的慢性丙型肝炎病毒（HCV）感染患者的百分比有所增加。然而，目前的标准pIFNa/RBV疗法不仅成功率低（约50%），而且往往伴有严重的副作用。因此，迫切需要开发新的抗HCV药物。亲环素（Cyp）抑制剂是最有前途的新的抗HCV药物正在开发中。最近的临床研究表明，Cyp抑制剂是有效的抗HCV药物，具有新颖的作用机制和疗效特征，使其成为与当前和未来HCV治疗组合的有吸引力的候选者。
The percentage of patients chronically infected with hepatitis C virus (HCV) who have reached sustained antiviral response has increased since the introduction of the pegylated interferon-alpha (pIFNa) and ribavirin (RBV) treatment. However, the current standard pIFNa/RBV therapy not only has a low success rate (about 50%) but is often associated with serious side effects. Thus, there is an urgent need for the development of new anti-HCV agents. Cyclophilin (Cyp) inhibitors are among the most promising of the new anti-HCV agents under development. Recent clinical studies demonstrate that Cyp inhibitors are potent anti-HCV drugs, with a novel mechanism of action and efficacy profiles that make them attractive candidates for combination with current and future HCV treatments.